Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rachelle S Doody

Showing results (1-10 of 98) with videos related to

Pageof 10
Sort By:
CNS Spectrums|November 5, 2008
Cholinesterase inhibitors and memantine: best practicesRachelle S Doody
The Journal of Clinical Psychiatry|August 26, 2003
Current treatments for Alzheimer's disease: cholinesterase inhibitorsRachelle S Doody
CNS Spectrums|November 6, 2009
Dimebon as a potential therapy for Alzheimer's diseaseRachelle S Doody
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|July 22, 2008
We should not distinguish between symptomatic and disease-modifying treatments in Alzheimer's disease drug developmentRachelle S Doody
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|March 31, 2009
Commentary on "a roadmap for the prevention of dementia II. Leon Thal Symposium 2008." Centers of excellence in Alzheimer's disease: it is time to better integrate patient care and clinical research to improve the prevention and treatment of Alzheimer's diseaseRachelle S Doody
Rinsho Shinkeigaku = Clinical Neurology|September 17, 2011
[Clinical trials in AD]Rachelle S Doody
Geriatrics|July 20, 2005
Refining treatment guidelines in Alzheimer's diseaseRachelle S Doody
Alzheimer'S Research & Therapy|June 3, 2011
Should persons with autosomal dominant AD be included in clinical trials? Authors' responseKinga Szigeti, Rachelle S Doody
Alzheimer'S Research & Therapy|February 25, 2011
Should EOAD patients be included in clinical trials?Kinga Szigeti, Rachelle S Doody
Alzheimer'S Research & Therapy|October 18, 2011
Progress in understanding variability in cognitive responses to cholinesterase inhibitor treatmentValory N Pavlik, Rachelle S Doody
Pageof 10

Showing results (1-10 of 98) with videos related to

Sort By:
Pageof 10
CNS Spectrums|November 5, 2008
Cholinesterase inhibitors and memantine: best practicesRachelle S Doody
The Journal of Clinical Psychiatry|August 26, 2003
Current treatments for Alzheimer's disease: cholinesterase inhibitorsRachelle S Doody
CNS Spectrums|November 6, 2009
Dimebon as a potential therapy for Alzheimer's diseaseRachelle S Doody
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|July 22, 2008
We should not distinguish between symptomatic and disease-modifying treatments in Alzheimer's disease drug developmentRachelle S Doody
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|March 31, 2009
Commentary on "a roadmap for the prevention of dementia II. Leon Thal Symposium 2008." Centers of excellence in Alzheimer's disease: it is time to better integrate patient care and clinical research to improve the prevention and treatment of Alzheimer's diseaseRachelle S Doody
Rinsho Shinkeigaku = Clinical Neurology|September 17, 2011
[Clinical trials in AD]Rachelle S Doody
Geriatrics|July 20, 2005
Refining treatment guidelines in Alzheimer's diseaseRachelle S Doody
Alzheimer'S Research & Therapy|June 3, 2011
Should persons with autosomal dominant AD be included in clinical trials? Authors' responseKinga Szigeti, Rachelle S Doody
Alzheimer'S Research & Therapy|February 25, 2011
Should EOAD patients be included in clinical trials?Kinga Szigeti, Rachelle S Doody
Alzheimer'S Research & Therapy|October 18, 2011
Progress in understanding variability in cognitive responses to cholinesterase inhibitor treatmentValory N Pavlik, Rachelle S Doody
Pageof 10